EPIRUS Biopharmaceuticals Probability of Future Pink Sheet Price Finishing Under 8.5E-5
| EPRSQDelisted Stock | USD 0.0001 0.00 0.00% |
EPIRUS |
EPIRUS Biopharmaceutica Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of EPIRUS Biopharmaceutica for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for EPIRUS Biopharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| EPIRUS Biopharmaceutica is not yet fully synchronised with the market data | |
| EPIRUS Biopharmaceutica has some characteristics of a very speculative penny stock | |
| EPIRUS Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| EPIRUS Biopharmaceuticals has accumulated 14.85 M in total debt with debt to equity ratio (D/E) of 0.57, which is about average as compared to similar companies. EPIRUS Biopharmaceuticals has a current ratio of 0.77, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist EPIRUS Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, EPIRUS Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like EPIRUS Biopharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for EPIRUS to invest in growth at high rates of return. When we think about EPIRUS Biopharmaceutica's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 701 K. Net Loss for the year was (52.19 M) with profit before overhead, payroll, taxes, and interest of 576 K. | |
| EPIRUS Biopharmaceuticals has accumulated about 20.86 M in cash with (46.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
EPIRUS Biopharmaceutica Technical Analysis
EPIRUS Biopharmaceutica's future price can be derived by breaking down and analyzing its technical indicators over time. EPIRUS Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of EPIRUS Biopharmaceuticals. In general, you should focus on analyzing EPIRUS Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
EPIRUS Biopharmaceutica Predictive Forecast Models
EPIRUS Biopharmaceutica's time-series forecasting models is one of many EPIRUS Biopharmaceutica's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary EPIRUS Biopharmaceutica's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about EPIRUS Biopharmaceuticals
Checking the ongoing alerts about EPIRUS Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for EPIRUS Biopharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| EPIRUS Biopharmaceutica is not yet fully synchronised with the market data | |
| EPIRUS Biopharmaceutica has some characteristics of a very speculative penny stock | |
| EPIRUS Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| EPIRUS Biopharmaceuticals has accumulated 14.85 M in total debt with debt to equity ratio (D/E) of 0.57, which is about average as compared to similar companies. EPIRUS Biopharmaceuticals has a current ratio of 0.77, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist EPIRUS Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, EPIRUS Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like EPIRUS Biopharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for EPIRUS to invest in growth at high rates of return. When we think about EPIRUS Biopharmaceutica's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 701 K. Net Loss for the year was (52.19 M) with profit before overhead, payroll, taxes, and interest of 576 K. | |
| EPIRUS Biopharmaceuticals has accumulated about 20.86 M in cash with (46.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in EPIRUS Pink Sheet
If you are still planning to invest in EPIRUS Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EPIRUS Biopharmaceutica's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |